SecProbe.io

CORRESP
1
filename1.htm

CytoMed
Therapeutics Limited

1
Commonwealth Lane

#08-22

Singapore
149544

+65
6250 7738

VIA
EDGAR

January
31, 2023

U.S.
Securities & Exchange Commission

Division
of Corporation Finance

Office
of Life Sciences

100
F Street, NE

Washington,
D.C. 20549

Attn:
Tracie Mariner

    Re:
    CytoMed
    Therapeutics Limited

    (f/k/a
    CytoMed Therapeutics Pte. Ltd.)

    Registration Statement
    on Form F-1

    Filed November 18, 2022

    File No. 333-268456

Dear
Ms. Mariner:

CytoMed
Therapeutics Limited (the “Company,” “we,” “our” or “us”)
hereby transmits our response to the comment letter received from the staff (the “Staff,” “you”
or “your”) of the U.S. Securities and Exchange Commission (the “Commission”), on November 30, 2022,
regarding Registration Statement on Form F-1 submitted to the Commission on November 18, 2022.

For
your convenience, we have repeated below your comments in bold, and have followed each comment with our response. Disclosure changes
made in response to the Staff’s comments have been made in Amendment No. 1 to the Registration Statement (the “Amendment”),
which is being submitted to the Commission contemporaneously with the submission of this letter.

Registration
Statement on Form F-1

Cover
Page

    1.
    Revise the disclosure
    on the cover page to clarify whether the offering is contingent upon final approval of your NASDAQ listing. Please ensure the disclosure
    is consistent with your underwriting agreement.

Response:
The Company respectfully acknowledges the Staff’s comment and has revised the cover page of the Amendment accordingly.

Risks
Related to Investments in Singapore Companies, page 68

    2.
    In the new risk factor
    on page 70 you disclose that Singapore taxes may differ from the tax laws of other jurisdictions and advise potential investors to
    consult with their own tax advisors; however, you provide no context regarding the nature of the potential risks. Please revise explain
    the risks you are attempting to convey.

Response:
The Company respectfully acknowledges the Staff’s comment and has revised page 70 of the Amendment accordingly.

Business

Patent
License, page 115

    3.
    Revise to disclose the
    term of the third extension of the patent license.

Response:
The Company respectfully acknowledges the Staff’s comment and notes that Exhibit 10.6 to the Registration Statement on Form
F-1 attaching the third extension of the patent license (the “Third Addendum”) has been redacted because the Company
considers the redacted terms of the Third Addendum to be not material and the type that the Company treats as private and confidential.

Exhibits

    4.
    Prior to effectiveness,
    file actual consents of all persons who will become directors, rather than “Form of” consents, or revise the exhibit
    index to clarify you have done so.

Response:
The Company respectfully acknowledges the Staff’s comment and has filed as Exhibits 99.1 to 99.7 to the Amendment the consents
of all persons who will become directors, respectively.

***

We
thank you for your review of the foregoing. If you have further comments, please feel free to contact to our counsel, Richard I. Anslow,
Esq., at ranslow@egsllp.com or by telephone at (212) 370-1300.

    Sincerely,

    /s/ Chee
    Kong CHOO

    Chee Kong CHOO

    Director and Chairman

    cc:
    Richard I. Anslow, Esq.

    Ellenoff Grossman & Schole LLP